Cory Perla

3 weeks ago | healio.com | Jay Chhablani |Cory Perla

SALT LAKE CITY — In this video, Jay Chhablani, MD, professor of ophthalmology at University of Pittsburgh School of Medicine, discusses a preliminary study of combination gene therapy targeting neovascular age-related macular degeneration. The therapy, a combination of AIBP, apoA-I and aflibercept, showed promise in a mouse study presented at the ARVO meeting, Chhablani said.

3 weeks ago | healio.com | Jay Chhablani |Cory Perla

SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses preliminary data from the ArMaDa study of OCU410 gene therapy for geographic atrophy presented at the ARVO meeting. In this phase 1/2 open-label dose-escalation trial, nine patients received a subretinal injection of low-dose, medium-dose or high-dose OCU410 (Ocugen), which delivers the RORA gene.

4 weeks ago | healio.com | Jay Chhablani |Cory Perla

SALT LAKE CITY — In this video, Jay Chhablani, MD, professor of ophthalmology at University of Pittsburgh School of Medicine, discusses 24-month findings from the SAGA trial evaluating oral gildeuretinol for geographic atrophy. Daily 14 mg gildeuretinol (Alkeus Pharmaceuticals) was associated with a reduction in GA lesion growth, with greater reductions occurring between months 6 and 24, Chhablani said. Patients also had less visual acuity loss and improved quality of life scores, he said.

1 month ago | healio.com | Jay Chhablani |Cory Perla

SALT LAKE CITY — In this video, Jay Chhablani, MD, discusses findings presented at the ARVO meeting from a phase 2b study evaluating suprachoroidal axitinib for neovascular age-related macular degeneration. The trial enrolled 60 previously treated patients with stable vision and compared suprachoroidal axitinib (Clearside Biomedical) with intravitreal aflibercept 2 mg (Regeneron).

Feb 24, 2025 | healio.com | Cory Perla |Mindy Valcarcel

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.